Itzhak Brook, MD, MSc (Table 2). Some postulate that bacterial interactions between GABHS and members of the pharyngotonsillar bacterial flora can explain these failures. These explanations include the shielding of GABHS from penicillins by β-lactamase-producing bacteria (BLPB) that colonize the pharynx and tonsils, 8 the absence T he frequently reported inability of penicillin to eradicate group A β-hemolytic streptococci (GABHS) from patients with acute and relapsing pharyngotonsillitis despite its excellent in vitro efficacy is a cause for concern. Two randomized, single-blind, multicenter antibiotic efficacy trials in children illustrated that the recommended doses of either oral penicillin V or intramuscular penicillin failed to eradicate GABHS in acute-onset pharyngitis in 35% of patients treated with oral penicillin V and 37% of those treated with intramuscular penicillin. 1 Several clinical studies 2-7 have demonstrated the low (57%) success rate of penicillin in contrast to other antibiotics (clindamycin, amoxicillin-clavulanate, and cephalosporins) in the treatment of relapsing pharyngotonsillitis (Table 1).Various theories have been offered to explain why this penicillin failure may lead to recurrent tonsillitis The causes of penicillin failure in eradicating group A β-hemolytic streptococcal (GABHS) pharyngotonsillitis that are due to microbiological interactions are described. These include the presence of β-lactamaseproducing bacteria that protect GABHS from penicillins, the absence of bacteria that interfere with the growth of GABHS, and coaggregation between GABHS and Moraxella catarrhalis. Antimicrobials that can overcome and modulate these phenomena achieve better cure of the infection than penicillins. The agents more effective than penicillins in the treatment of acute infections included the cephalosporins and macrolides, and those more effective in the treatment of chronic infections included clindamycin and amoxicillin-clavulanate.